Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer

Overview of attention for article published in World Journal of Urology, January 2005

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)

Mentioned by

patent: 9 patents

Citations

dimensions_citation: 85 Dimensions

Readers on

mendeley: 35 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 9 patents that reference this research output.

Methods and compositions for treating cancer

Grant US-10702540-B2

United States of America

Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer

Grant US-9822170-B2

United States of America

Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor…

Grant US-9512211-B2

United States of America

Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides

Grant US-9095602-B2

United States of America

TRPM-2 antisense therapy

Grant US-9074209-B2

United States of America

Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor…

Grant US-8802826-B2

United States of America

TRPM-2 antisense therapy

Grant US-8536149-B2

United States of America

Methods and compositions for modulating tumor cell activity

Grant US-8426562-B2

United States of America

ANTI-CLUSTERIN ANTIBODIES AND ANTIGEN BINDING FRAGMENTS AND THEIR USE TO REDUCE TUMOR…

Application WO-2011063523-A1

World Intellectual Property Organisation (WIPO)